Parkinson’s Progressive Marker Initiative PPMI - (still enrolling)
This study will collect clinical information, samples of blood, DNA, urine, cerebral spinal fluid, and brain images from subjects with PD and from subjects without PD. . This information will be used to help develop biomarkers for PD. Biomarkers are measures that tell something about PD. This study is looking at biomarkers in PD because they may help to understand how the disease changes over time. Having good biomarkers for PD may also be useful in developing new treatments and may help to improve clinical care in the future. In this study we will test biomarkers that may be related to the way PD changes over time.
To qualify: Age 18 and above with or without PD.
Biogen (actively recruiting)
The purpose of the study is to find out whether the study medication has the potential to be a helpful treatment that slows down disease progression in subjects with early Alzheimer’s disease by comparing it to placebo, to evaluate its safety (side effects), and to find out more about the study medication. Ages 50-85.
USC A4 LZAZ (actively recruiting healthy volunteers)
The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s study (the “A4 study”) is a clinical trial for older individuals who may be at risk for Alzheimer’s disease memory loss.
The A4 study is testing an anti-amyloid investigational drug in older individuals who have evidence of elevated amyloid build-up in their brains, but who do not show symptoms of AD in order to slow possible AD-related damage in the brain and to delay progression of AD-related memory loss.
The purpose of this study is to test whether an investigational drug can slow the progression of memory problems associated with brain amyloid.
To qualify: Age of 65-85 with no history of or complaint of memory problems.
The purpose of the study is to:
- Test the safety and how well a person tolerates two doses of the research study drug MK-8931 in subjects with Amnestic Mild Cognitive Impairment (aMCI) due to Alzheimer's Disease (AD).
- Assess the effect of two doses of MK 8931 on disease progression (disease getting worse) in subjects with aMCI due to AD.
To qualify: Age of 50-85 diagnosed with Mild Cognitive Impairment and no diagnosis of Alzheimer’s disease.
Astra Zeneca AMARANTH study
The purpose of this study is to see if the drug AZD3293 is effective and safe in treating early Alzheimer’s disease compared with placebo.
To qualify: Age 55-85 with a diagnosis of Mild Cognitive Impairment or early Alzheimer’s disease.